Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Furiex Pharmaceuticals, Inc. (FURX)

-NasdaqGS
75.24 Down 1.88(2.44%) Apr 17, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Furiex Pharmaceuticals, Inc.
3900 Paramount Parkway
Suite 150
Morrisville, NC 27560
United States - Map
Phone: 919-456-7800
Website: http://www.furiex.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drugs - Generic
Full Time Employees:24

Business Summary 

Furiex Pharmaceuticals, Inc. operates as a drug development company that is involved in compound development and collaboration activities primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company holds rights to royalties and regulatory and sales-based milestone payments for alogliptin, alogliptin combination products, and SYR-472 (trelagliptin) for the treatment of Type-2 diabetes, which are marketed under the Nesina and Liovel names in Japan, as well as under the Nesina, Oseni, and Kazano names in the United States. It also owns rights to royalties and sales-based milestones for Priligy (dapoxetine) for premature ejaculation, which is marketed in approximately 30 countries in Europe, the Asia-Pacific, and Latin America. In addition, the company holds license rights to eluxadoline (MuDelta), a novel, orally active, investigational agent, which is in Phase III development diarrhea-predominant irritable bowel syndrome, and to JNJ-Q2, a novel, fluoroquinolone antibiotic, which is in Phase III development for skin and lung infections. It markets its products through third party collaborators. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Furiex Pharmaceuticals, Inc.

Corporate Governance 
Furiex Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 4. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. June S. Almenoff M.D., Ph.D., F.A.C.P., 57
Pres, Chief Medical Officer and Director
534.00K0.00
Mr. Sailash I. Patel , 56
Chief Financial Officer, Principal Accounting Officer and VP of Strategic Devel.
335.00K0.00
Dr. Paul S. Covington M.D., 58
Sr. VP of Clinical Devel. & Operations
470.00K953.00K
Dr. Gail F. McIntyre Ph.D., CH (ASCP), DABT, 51
Sr. VP of Research
409.00K617.00K
Dr. Nadine C. Chien Ph.D., Esq.,
VP of Legal Affairs and Sec.
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders